Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 12, 2006, Pages 4038-4043

  Kornbluth, Richard S ^a,b   Smee, Donald F ^c   Sidwell, Robert W ^c   Snarsky, Victoria ^a,b   Evans, David H ^d   Hostetler, Karl Y ^a,b,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UTAH STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; AMINO ACID; CIDOFOVIR; DNA POLYMERASE; E9L POLYMERASE; EXONUCLEASE; HEXADECYLOXYPROPYLCIDOFOVIR; NUCLEOSIDE ANALOG; PLACEBO;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; E9L POLYMERASE GENE; FEMALE; GENE MUTATION; GENE SEQUENCE; INFECTION PREVENTION; LETHALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; SEQUENCE ANALYSIS; SMALLPOX; VACCINIA VIRUS; VERO CELL; VIRUS GENE; VIRUS VIRULENCE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CYTOSINE; DISEASE MODELS, ANIMAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; MICE; MICE, INBRED BALB C; MUTATION; PHENOTYPE; PHOSPHONIC ACIDS; SPECIFIC PATHOGEN-FREE ORGANISMS; VACCINIA; VACCINIA VIRUS; VERO CELLS;

EID: 33845245359     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00380-06     Document Type: Article

References (28)

1. Alba, M. 2001. Replicative DNA polymerases. Genome Biol. 3:REVIEWS3002.1. [Online.] http://genomebiology.com/2001/2/1/reviews/3002.
2. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 57:13-23.
3. Beadle, J. R., N. Rodriquez, K. A. Aldern, C. Hartline, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.
4. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. S. Infect. Dis. 181:10-19.
5. De Clercq, E., and J. Neyts. 2004. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. Med. Virol. 55:1-13.
6. Earl, P. L., E. V. Jones, and B. Moss. 1986. Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene. Proc. Natl. Acad. Sci. USA 83:3659-3663.
7. Earl, P. L., and B. Moss. 2003. Unit 16.18. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. Greene & Wiley, New York, N.Y.
8. Gubser, C., and G. L. Smith. 2002. The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J. Gen. Virol. 83:855-872.
9. Kaplan E. H., and L. M. Wein. 2003. Smallpox bioterror response. Science 300:1503-1504.
10. Kern, E. R. 2003. In vitro activity of potential anti-poxvirus agents. Antivir. Res. 57:35-40.
11. Klemperer, N., W. McDonald, K. Boyle, B. Unger, and P. Traktman. 2001. The A20R protein is a stoichiometric component of the processive form of vaccinia virus DNA polymerase. J. Virol. 75:12298-12307.
12. Magee, W. C., K. Y. Hostetler, and D. H. Evans. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49:3153-3162.
13. Miller, V., and B. A. Larder. 2001. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir. Ther. 6(Suppl. 3):25-44.
14. Neyts, J., and E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2- phosphonyl-methoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:242-246.
15. Neyts, J., and E. De Clercq. 2001. Efficacy of 2-amino-7-(1,3-dihydroxy- 2-propoxymethyl)purine treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 45:84-87.
16. Quenelle, D. C., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.
17. Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
18. Shamoo, Y., and T. A. Steitz. 1999. Building a replisome from interacting pieces: sliding clamp complexed to a peptide from DNA polymerase and a polymerase editing complex. Cell 99:155-166.
19. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2001. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:71-76.
20. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2002. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2- propoxy)methyl]purinc and its orally active diacetate ester prodrug. Antivir. Res. 54:113-120.
21. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329-1335.
22. Smee, D. F., and R. W. Sidwell. 2003. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antivir. Res. 57:41-52.
23. Smee, D. F., M. K. Wandersee, K. W. Bailey, K. Y. Hostetler, A. Holy, and R. W. Sidwell. 2005. Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir. Chem. Chemother. 16:203-211.
24. Smee, D. F., M.-H. Wong, K. W. Bailey, J. R. Beadle, K. Y. Hostetler, and R. W. Sidwell. 2004. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents 23:430-437.
25. Tacke, F., M. P. Manns, and C. Trautwein. 2004. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance - implications for novel antiviral strategies. Curr. Med. Chem. 11:2667-2677.
26. Taddie, J. A., and P. Traktman. 1993. Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3′-5′ exonuclease domain. J. Virol. 67:4323-4336.
27. Taddie, J. A., and P. Traktman. 1991. Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity. J. Virol. 65:869-879.
28. Thompson, C. L., and R. C. Condit. 1986. Marker rescue mapping of vaccinia virus temperature-sensitive mutants using overlapping cosmid clones representing the entire virus genome. Virology 150:10-20.